Latest Drug delivery Stories
A major breakthrough in the quest for oral insulin was announced by Dr. Daniel DeBrouse, CEO, CSO of Tamarisk Technologies of Meeker, OK. This comes just days after his publishing of nearly a decade of research in oral drug delivery. Tamarisk Technologies is already in licensing talks with several big pharmas. Meeker, OK (PRWEB) May 09, 2012 "The data doesn't lie," said Dr DeBrouse. "After years of research, I am happy to say, not only have we achieved our goal of providing the world with...
Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges. They report their proof of principle findings in the April 30, 2012 early online edition of Proceedings of the National Academy of Sciences. Wortmannin is a drug that was...
YORK, Pa., April 26, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) today announced financial results for the quarter ended March 31, 2012 (the third quarter of Fiscal Year 2012). Recent Highlights: Supplying pharmaceutical companies with shipments of the Unifill ready-to-fill (prefilled) syringe. Further expansion of the Unilife AutoInfusor platform of wearable, disposable pumps for the self-administration of large-volume dose....
LONDON, April 11, 2012 /PRNewswire/ -- Based on its recent analysis of the responsive polymer for bio-medical application market, Frost & Sullivan recognises CIS Pharma with the 2011 European Frost & Sullivan Technology Innovation Award for its unique Cellophil(TM) bio-medical polymer technology. "This novel temperature-responsive polymer, based on bi-functional amino-acids, exhibits superior biocompatibility, while resolving biocompatibility issues such as bio-film and...
Rice teams with MD Anderson, Baylor College of Medicine to explore drug and gene delivery Using light-harvesting nanoparticles to convert laser energy into “plasmonic nanobubbles,” researchers at Rice University, the University of Texas MD Anderson Cancer Center and Baylor College of Medicine (BCM) are developing new methods to inject drugs and genetic payloads directly into cancer cells. In tests on drug-resistant cancer cells, the researchers found that delivering chemotherapy drugs...
BOONTON, N.J., March 29, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that David Moskowitz, Chief Financial Officer, will present a corporate overview at the 11th Annual Needham Healthcare Conference 2012 in New York, NY. Mr. Moskowtiz's presentation is scheduled to begin at 2:40 p.m. ET on Wednesday, April 4, 2012. A live webcast of the presentation will be...
YORK, Pa., March 22, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS) announced today that it will host an Analyst and Investor Day on Wednesday, March 28th from 8:00am to 12:00pm ET in New York City. Alan Shortall, Chief Executive Officer of Unilife, will give a brief introduction, and then Dr. Ramin Mojdeh, Chief Operating Officer at Unilife will moderate a series of presentations from several members of Unilife's management team....
HAMPTON, N.J., March 21, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the Center for Devices and Radiological Health (CDRH) branch of the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for compatibility of its INOMAX drug-delivery systems with three additional respiratory care devices. The INOMAX DS and the INOMAX DSIR have now been...
MIAMI, March 21, 2012 /PRNewswire/ -- Fuisz Pharma today announced the filing of a patent application with the United States Patent and Trademark Office relating to the field of breath-based diagnostic systems. Joseph Matus Fuisz Esq., commented, "The field of breath diagnostics holds enormous potential to extend the range of convenient and portable non-invasive diagnostic techniques. This patent application is directed towards addressing some of the challenges that have prevented...
BEDMINSTER, N.J., March 19, 2012 /PRNewswire/ -- Nautilus Neurosciences announced today that their Canadian promotional partner, Tribute Pharmaceuticals, a wholly owned subsidiary of Stellar Pharmaceuticals, was granted a Notice of Compliance (NOC) approval from Health Canada for CAMBIA® (diclofenac potassium for oral solution) in the treatment of acute migraine with or without aura in adults. CAMBIA® is expected to be launched in Canada during the second half of 2012. CAMBIA® has...
